Lisinopril angiotensin-Converting Enzyme Inhibitors

Description Results NMA

lisinopril (5 mg initial dose and then 10 mg daily) for 42 days (n=9435)

vs.

open control (n=9460)

open

Factorial plan

Sample size: 9435/9460

Primary endpoint: all cause mortality

FU duration: 6 months

AF 0.92 [0.83; 1.01]

lisinopril (n=8902)

vs.

placebo (n=8846)

Sample size: 8902/8846

Primary endpoint:

FU duration: 0.5 y

AF recurrence 0.45 [0.13; 1.57]

lisinopril (n=7)

vs.

placebo (n=11)

double blind

Parallel groups

Sample size: 7/11

Primary endpoint:

FU duration: 84 days

All deaths 0.99 [0.89; 1.10]

Stroke 1.06 [0.89; 1.26]

Fatal and nonfatal MI 1.03 [0.94; 1.13]

Cardiovascular events 1.07 [0.99; 1.15]

lisinopril 10 to 40 mg/d (n=2431)

vs.

chlorthalidone 12.5 to 25 mg/d (n=4498)

double-blind

Parallel groups

Sample size: 2431/4498

Primary endpoint: fatal CHD or nonfatal MI

FU duration: 4.9 y

all cause death or hospitalisation 0.84 [0.20; 3.43]

all cause death or hospitalisation 0.32 [0.09; 1.10]

all cause death or hospitalisation 1.07 [0.07; 16.32]

all cause death or hospitalisation NaN [NaN; NaN]

(n=183)

vs.

(n=92)

Sample size: 183/92

Primary endpoint:

FU duration:

(n=130)

vs.

(n=63)

Sample size: 130/63

Primary endpoint:

FU duration:

(n=28)

vs.

(n=30)

Sample size: 28/30

Primary endpoint:

FU duration:

lisinopril (n=14)

vs.

placebo (n=14)

double blind

Cross over

Sample size: 14/14

Primary endpoint:

FU duration: 12 weeks

lisnopril titrated up to 10mg daily (n=87)

vs.

placebo (n=43)

double blind

Parallel groups

Sample size: 87/43

Primary endpoint: exercise tolerance

FU duration: 12 weeks

lisinopril low dose 2.5-5 mg daily (n=1596)

vs.

lisnopril high dose 32.5-35 mg daily (n=1568)

double blind

Parallel groups

Sample size: 1596/1568

Primary endpoint: all cause mortality

FU duration: 39 to 58 months

heart failure 0.87 [0.78; 0.96]

stroke (fatal & non fatal) 1.21 [1.06; 1.38]

all cause death 1.05 [0.97; 1.12]

coronary heart disease 1.00 [0.91; 1.09]

cardiovascular death 1.03 [0.92; 1.15]

fatal MI 0.93 [0.75; 1.16]

fatal stroke 1.27 [0.97; 1.67]

Major cardiovascular events 1.03 [0.99; 1.08]

end stage renal disease 0.98 [0.76; 1.25]

non cardiovascular death 1.08 [0.97; 1.21]

Lisinopril 10 to 40 mg/d (n=9054)

vs.

amlodipine 2.5 to 10 mg/d (n=9048)

Double blind

Parallel groups

Sample size: 9054/9048

Primary endpoint: fatal CHD or nonfatal myocardial infarction

FU duration: 4.9 y

heart failure 1.19 [1.07; 1.31]

stroke (fatal & non fatal) 1.14 [1.02; 1.28]

Major cardiovascular events 1.07 [1.03; 1.12]

all cause death 1.00 [0.94; 1.07]

coronary heart disease 0.98 [0.91; 1.07]

cardiovascular death 1.03 [0.94; 1.14]

fatal MI 0.89 [0.73; 1.08]

fatal stroke 1.20 [0.95; 1.52]

end stage renal disease 1.10 [0.88; 1.37]

non cardiovascular death 0.97 [0.88; 1.06]

All deaths 0.99 [0.89; 1.10]

Stroke 1.06 [0.89; 1.26]

Fatal and nonfatal MI 1.03 [0.94; 1.13]

Cardiovascular events 1.07 [0.99; 1.15]

lisinopril 10 to 40 mg/d (n=9054)

vs.

chlorthalidone 12.5 to 25 mg/d (n=15255)

Double blind

Parallel groups

Sample size: 9054/15255

Primary endpoint: fatal CHD or nonfatal myocardial infarction

FU duration: 4·9 y

lisinopril 10 to 40 mg/d (n=2431)

vs.

chlorthalidone 12.5 to 25 mg/d (n=4498)

double-blind

Parallel groups

Sample size: 2431/4498

Primary endpoint: fatal CHD or nonfatal MI

FU duration: 4.9 y